T1	Participants 365 446	evaluated in a large number of human volunteers in India, Vietnam, and Bangladesh
T2	Participants 607 696	evaluated the safety and immunogenicity of the vaccine in 216 healthy adults and children
T3	Participants 805 811	adults
T4	Participants 820 828	children
